{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFIRINOX&page=2", "query": { "intervention": "FOLFIRINOX", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFIRINOX&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-15T18:38:50.160Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01928290", "title": "Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stomach Neoplasms", "Esophageal Neoplasms" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2013-11-08", "completion_date": "2019-10-28", "has_results": true, "last_update_posted_date": "2020-08-25", "last_synced_at": "2026-09-15T18:38:50.160Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01928290" }, { "nct_id": "NCT07621718", "title": "Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Cancer Metastatic", "PDAC", "PDAC - Pancreatic Ductal Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Pancreatic Adenocarcinoma Metastatic", "Pancreatic Adenocarcinoma", "Pancreatic Adenosquamous Carcinoma" ], "interventions": [ { "name": "Zoldonrasib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin (Calcium Folinate)", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Gemcitabine (GEM)", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 670, "start_date": "2026-05-22", "completion_date": "2030-04-22", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-15T18:38:50.160Z", "location_count": 9, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Tampa, Florida + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07621718" }, { "nct_id": "NCT05417386", "title": "FOLFIRINOX + NIS793 in Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreas Cancer", "Metastatic Pancreatic Cancer", "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "NIS793", "type": "DRUG" }, { "name": "Chemoradiation", "type": "RADIATION" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Colin D. Weekes, M.D., PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2022-08-09", "completion_date": "2023-07-10", "has_results": false, "last_update_posted_date": "2025-11-18", "last_synced_at": "2026-09-15T18:38:50.160Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05417386" }, { "nct_id": "NCT05382559", "title": "A Study of ASP3082 in Adults With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Setidegrasib", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Nanoparticle albumin-bound-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Liposomal Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 681, "start_date": "2022-06-08", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-15T18:38:50.160Z", "location_count": 26, "location_summary": "Duarte, California • Santa Monica, California • Denver, Colorado + 20 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05382559" }, { "nct_id": "NCT07627191", "title": "GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Pancreatic Cancer", "Colorectal Cancer", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "GLP1-RA (semaglutide)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 30, "start_date": "2026-07-10", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-09-15T18:38:50.160Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07627191" }, { "nct_id": "NCT02575508", "title": "Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colon Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Pancreatic Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma", "Rectal Adenocarcinoma", "Stage III Pancreatic Cancer", "Stage IIIA Colon Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Colon Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Colon Cancer", "Stage IIIC Rectal Cancer", "Stage IV Pancreatic Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "pan FGFR Kinase Inhibitor BGJ398", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2016-05-20", "last_synced_at": "2026-09-15T18:38:50.160Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02575508" }, { "nct_id": "NCT05546411", "title": "A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Resectable Pancreatic Cancer", "Borderline Resectable Pancreatic Adenocarcinoma", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "mFOLFIRINOX", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "NIS793", "type": "DRUG" }, { "name": "Chemoradiation", "type": "RADIATION" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Kimberly Perez, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2023-01-06", "completion_date": "2023-10-13", "has_results": true, "last_update_posted_date": "2024-12-17", "last_synced_at": "2026-09-15T18:38:50.160Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05546411" }, { "nct_id": "NCT01836432", "title": "Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer", "Pancreatic Carcinoma Non-resectable", "Locally Advanced Malignant Neoplasm" ], "interventions": [ { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "Algenpantucel-L Immunotherapy", "type": "BIOLOGICAL" }, { "name": "5-FU Chemoradiation", "type": "RADIATION" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2013-05", "completion_date": "2017-03-24", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-09-15T18:38:50.160Z", "location_count": 32, "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stamford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01836432" }, { "nct_id": "NCT05458219", "title": "A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Unresectable or Metastatic Solid Tumors" ], "interventions": [ { "name": "IBI343", "type": "DRUG" }, { "name": "FOLFIRINOX/mFOLFIRINOX", "type": "DRUG" }, { "name": "mFOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 470, "start_date": "2022-10-26", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-09-15T18:38:50.160Z", "location_count": 3, "location_summary": "Austin, Texas • Irving, Texas • San Antonio, Texas", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Irving", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05458219" }, { "nct_id": "NCT01676259", "title": "A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Pancreatic Cancer" ], "interventions": [ { "name": "siG12D-LODER", "type": "DRUG" }, { "name": "Gemcitabine+nab-Paclitaxel", "type": "DRUG" }, { "name": "Folfirinox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Silenseed Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2018-03-07", "completion_date": "2023-08", "has_results": false, "last_update_posted_date": "2021-07-02", "last_synced_at": "2026-09-15T18:38:50.160Z", "location_count": 4, "location_summary": "Hackensack, New Jersey • New York, New York • Houston, Texas", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01676259" } ] }